<DOC>
	<DOCNO>NCT02058173</DOCNO>
	<brief_summary>The purpose study assess efficacy Chloroquine compare placebo treatment non- response HCV patients.. In triple blind pilot study , 20 patient confirm chronic hepatitis C randomize treatment group ( Chloroquine 150 mg daily , 8 week ) control group ( placebo daily , 8 week ) . Patients receive anti neoplastic , anti viral Immunomedullator drug 6 month prior study , co-infection Hepatitis A , C , D HIV , severe liver renal dysfunction , pregnant breast fed , refuse sign inform consent excluded.. At end therapy ( 12 week ) baseline , first , second third month receive drug placebo HCV Virus load , CBC LFT biochemical parameter evaluate compare group .</brief_summary>
	<brief_title>`` Pharmacoepidemiological Evaluation Autophagy Inhibition Treatment HCV Patients Resistant Standard Therapy . Pilot Study ''</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<criteria>patient fail achieve decline 2 log HCV RNA IU/ml 12 week treatment never achieve undetectable HCV RNA treatment minimum duration 24 week Receiving anti neoplasm , anti viral immunomedulator drug 6 month prior study coinfection Hepatitis A , C , D viruses HIV Severe dysfunction liver kidney pregnancy breast feed refuse give inform consent active Alcohol user presence decompensate cirrhosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>